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Abstract 
 
Opioid abuse and addiction affects more than 2.4 million people in the United 
States. Medication assisted treatment (MAT), in combination with counseling, is 
recognized as the most effective treatment for patients with opioid dependence and 
abuse. Although MAT is considered the most effective treatment, previous research 
has found clinically significant weight gain with methadone. The purpose of this 
study was to determine if hedonic eating behaviors, sugar cravings, and addictive like 
eating was related to weight gain in opioid addicted patients receiving methadone and 
buprenorphine/naloxone (Suboxone™). Hedonic eating behaviors were measured 
using three validated surveys. Following survey collection, a chart review was 
completed to determine weight changes over time.  One hundred twenty surveys were 
completed and 113 were analyzed. No differences were found between the 
medication groups in terms of mean age, weight at entry, BMI at entry, race, sex, and 
Hepatitis C status. A subset of 39 participants was analyzed for weight changes 
during treatment. There were no differences in food addiction scores, hedonic eating 
behaviors, and food cravings between the medication groups. We found significant 
weight gain in patients receiving methadone and no weight changes for those 
receiving Suboxone™. Weight gain in methadone maintenance does not appear to be 
related to addictive like eating, food craving, or hedonic eating. This research 
suggests that weight gain seen in methadone maintenance for opioid addiction 
treatment is related to something other than hedonic eating behaviors. Clinically 
significant weight gain should be considered when prescribing methadone for opioid 
addiction.  
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Introduction 
 
Opioid abuse and addiction affect over 2.4 million people in the United States. In 
2014, 1.9 million people abused prescription pain medication and 586,000 people were 
addicted to heroin (Substance Abuse and Mental Health Services Administration, 2015). 
In Vermont alone, nearly 4,000 people are currently in treatment for opioid addiction 
(Vermont Department of Health, 2014). Medication assisted treatment (MAT), in 
combination with counseling, is recognized as the most effective treatment for patients 
with opioid dependence and abuse (Stotts, Dodrill, & Kosten, 2009). However, Fenn, 
Laurent, and Sigmon (2014) found a mean increase of 17.8 pounds for patients following 
entry into methadone treatment within, on average, the first 18 months of treatment. 
Although research supports the use of MAT for opioid addiction, the implications for 
weight gain are significant. Obesity is associated with higher risk for many serious 
diseases and health conditions including hypertension, type II diabetes, stroke, anxiety, 
depression, heart disease, and overall mortality (CDC, 2014).  
Methadone is a mu-opioid agonist (Yaksh &Wallace, 2011). In a systematic 
review, Mysels and Sullivan (2010) found that mu-opioid receptor activation is 
associated with increased preference for sweets, hyperglycemia, and potential insulin 
resistance. There is a growing body of research demonstrating that particular foods and 
food additives act on similar neural pathways as addictive drugs (Gearhardt et al., 2011).  
The literature also suggests that food addiction or addictive like eating is a contributing 
factor to obesity (Blumenthal & Gold, 2010).  Methadone is associated with significant 
weight gain, however, the mechanisms of this weight gain are not fully understood. 
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Volkow et al. (2002) describe neural pathways in individuals with food addiction 
consistent with neural pathways found in individuals with opioid addiction. It is plausible 
that some of the weight gain seen in methadone treatment for opioid addiction might be 
attributable to hedonic preferences toward highly sweetened foods.   
Additionally, substitute addiction, the process of replacing one addictive or 
compulsive behavior with another (McFadden, 2010), might be a plausible mechanism 
for increased food consumption and weight gain in methadone treatment. The literature 
on substitute addiction posits that for a substitute addiction to occur, the new compulsive 
behavior must replace at least one key function, such as pleasure or escape, previously 
achieved by a former addiction (Sussman & Black, 2008). This study may provide 
additional evidence into the potential contribution of substitute addiction and addictive 
like eating in medication assisted treatment for opioid addiction.  
It is unclear if buprenorphine, a partial mu-opioid agonist used in the treatment of 
opioid addiction, has similar effects as methadone on weight gain. Buprenorphine is 
increasingly used in addiction treatment in the primary care setting. Because 
buprenorphine and methadone affect the mu-opioid receptor differently, understanding 
weight changes in buprenorphine treatment compared to methadone may provide insight 
into overall hedonic mechanisms of weight gain in MAT. If differences between the two 
drugs in weight gain are determined, the weight gain may be more attributable to the drug 
side effects than to eating behavior. If, however, similar weight trends are observed 
between the two drugs, it is plausible that eating behavior is implicated in weight gain in 
MAT regardless of the medication used in treatment. 
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Purpose of the study  
The aim of this study is to determine the relationship between hedonic eating 
behaviors, sugar cravings, and weight gain in opioid addicted patients receiving 
medication assisted treatment. A secondary aim is to determine if there is a difference 
between weight gain and hedonic eating behaviors for individuals undergoing methadone 
compared to buprenorphine treatment. Our hypothesis is that hedonic eating behaviors 
and addictive like eating will be associated with weight gain in medication assisted 
treatment for opioid addiction for both methadone and buprenorphine. Despite the 
hedonic mechanisms, we expect greater weight gain in those receiving methadone than 
those receiving buprenorphine based on the pharmacodynamics of the drugs.  
Theoretical framework 
 Robinson and Berridge’s Incentive-Sensitization Theory will be utilized to inform 
study design and procedures. The theory suggests that in certain individuals with repeated 
exposure to a stimulus, a hypersensitivity response occurs in the brain and transforms the 
perception of that stimulus into pathological wanting. This pathological wanting is known 
as incentive salience. In certain individuals, repeated exposure to addictive drugs can 
alter the neural systems responsible for incentive salience to make an individual 
hypersensitive or sensitized to that drug and associated stimuli. This results in pathologic 
attachment to the drug and associated stimuli. Drug ‘wanting’ is then transformed into 
excessive drug craving. This can occur independently of the neural systems that mediate 
the pleasurable (‘liking’) and withdrawal effects of drugs, meaning that drug seeking may 
occur in absence of withdrawal or pleasure. As a result, addictive behaviors such as of 
compulsive drug seeking and taking occur despite strong desires to quit and 
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consequences of continued use. Neural adaption recurs and is responsible for drug 
wanting, which may last for years even after discontinued use (Robinson & Berridge, 
1993, Robinson & Berridge, 2008). Recent literature suggests that certain foods and food 
additives may trigger addictive process in the brain similar to those seen in drug addiction 
(Gearhardt, Corbin, & Brownell, 2008), suggesting similar pathological wanting. 
Significance 
With the potential obesity related health problems patients recovering from drug 
addiction may face, understanding the mechanism behind weight gain is essential in order 
to provide optimal care, minimize risks, and impart the most appropriate education for 
patients. A clearer understanding of the mechanisms of weight gain in MAT can alter 
treatment paradigms for nurse practitioners and other clinicians. The information gleaned 
from our study has the potential to create recommendations for a multidisciplinary 
treatment approach that includes nutrition support, mental health services, social service 
resources, and food and addiction counseling. This research will provide further 
understanding of the relationships among these phenomena and, in particular, of the 
hedonic mechanisms of weight gain in medication assisted treatment for opioid addiction, 
and may contribute to future research aimed at gathering empirical evidence on substitute 
addiction.   
APRN Competencies  
Several nurse practitioner core competencies as outlined by the National 
Organization of Nurse Practitioner Faculties are addressed within this study including 
scientific foundation, leadership, practice inquiry, policy, and ethics (NONPF,	  2012). 
The information discovered from this study has the potential to enhance the scientific 
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foundation from which advanced practice registered nurses (APRNs) practice in primary 
care by furthering the understanding of the implications and side effects of MAT. 
Advanced practice registered nurses provide direct care to individuals receiving MAT 
and may, in the future, be prescribers of MAT. Advanced practice registered nurses are in 
a key position to be leaders in addressing the ongoing opioid and obesity epidemics. It is 
expected that the study findings will be applicable to a broad inter-professional audience 
that provides full spectrum care to this underserved, high-risk population, furthering the 
policy, ethical, and leadership impacts.  
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Comprehensive Literature Review 
 This chapter outlines the current literature related to weight gain in patients 
receiving methadone for opioid addiction, sugar cravings in medication assisted treatment 
(MAT), and food addiction. It concludes by proposing a hypothesis for substitute 
addiction as a plausible mechanism for weight gain seen in MAT. At the time this 
literature review was prepared, the weight effects of buprenorphine were absent from the 
literature. 
Weight changes in medication assisted treatment  
 A 2005 study evaluated body mass index (BMI) and adiposity of opioid addicted 
patients (n=30) before treatment and after four years of treatment with methadone. The 
study compared BMI and mid arm muscle circumference (MAMC) in patients in 
treatment for opioid addiction.  At the four-year follow-up, female patients (n=7) had a 
decrease in BMI with the percentage of fatty tissue in general body mass significantly 
below recommended values. In male patients (n=23), BMI increased with a concurrent 
increase in MAMC. This suggested that weight changes in methadone treatment may 
differ by gender. The study may not be generalizable to a US population and was 
significantly limited by its small sample size. Little statistical generalizability can be 
gleaned from the female population based on the sample size (Kolarzyk et al., 2005). 
Despite these limitations, this study provided early insight to potential differential effects 
of weight gain in men receiving methadone treatment.  
In a retrospective chart review, Fenn, Laurent, and Sigmon (2014) examined 
changes in body mass index (BMI) among patients participating in methadone treatment 
for opioid addiction. Health records of 96 non-pregnant, opioid-dependent adults enrolled 
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in an outpatient methadone treatment program for at least 6 months between 2002-2011 
were analyzed. Significant increases in BMI were found following entry into methadone 
treatment. The mean BMI increased from 27.2 to 30.1 kg/m2, representing a mean weight 
gain of 17.8 lbs.  A significant difference between female and male weight gain was 
observed with female patients gaining on average of 28 pounds compared to men who 
had an average increase of 12 pounds. Collectively, this represented clinically significant 
weight gain (Donnelly et al., 2009).  This study provided evidence that methadone may 
contribute to weight gain, but the mechanisms behind the weight gain were not 
addressed. These findings were in contrast to Kolarzyk et al. (2005) who reported a 
decrease in adiposity in females. The sample size was small (n=7) which may explain this 
descrepency. Confounding medication use was not isolated. 
Mysels et al. (2011) conducted a retrospective chart review to compare weight 
changes in patients on naltrexone compared to methadone. Health records of 36 opioid-
dependent patients within the first six months of treatment were reviewed. Both groups 
showed significant weight gain compared to baseline weight.  At six months, the 
methadone maintained group had a mean increase in weight of 3.67% and the naltrexone 
group had a 4.63% increase compared to baseline. There was no statistically significant 
difference between the groups in weight gain at xix months. Strengths of this study 
include that it compared both treatments. The sample size was small, which limited the 
power of the study. The study was also limited in that it compared different clinics each 
with different treatment protocols. Although the data was limited, these results suggest 
that medication side effects alone may not account for weight gain found in medication 
assisted treatment. If so, one would expect to see differing weight gain between the 
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methadone and naltrexone. Similarly, if weight gain on methadone maintenance was 
attributable to an increase in sugar cravings alone, one would not expect to see an 
increase in weight with administration of an opioid antagonist such as naltrexone. This 
may suggest hedonic mechanisms as a potential etiology of weight gain in MAT 
regardless of drug.   
Okruhlica and Slexakova (2012) explored the question of whether weight gain 
with methadone maintenance treatment was stable over time or transitory. The authors 
also examined the possible contributions of pharmacological and sociologic factors on 
body weight changes in methadone maintenance treatment.  This longitudinal, 
observational study included 42 patients participating in a methadone maintenance 
program in Slovakia.  Significant increases in mean BMI change were seen after one year 
and a less significant increase between one and two years.  Further, no statistically 
significant weight changes were found between one and four years after entry into 
treatment.  These findings suggest weight gain is more significant in the first year of 
treatment and plateaus after year two.  No association was found between amount of 
weight gain and dose of medication. This lack of association adds evidence suggesting 
eating behavior and sociologic factors might play more of a role in the weight gain than 
the pharmacological factors, particularly early in treatment.   
Parvaresh, Sabahi, Mazhari, and Gilani (2015) investigated the effects of 
methadone treatment on sexual function, sleep, and weight after six months of MAT. The 
cross-sectional study used a convenience sample of patients (n=199) from a methadone 
clinic in Iran.  Patients were weighed at the beginning and end of treatment. Additionally, 
all patients completed demographic questionnaires, sleep and sexual experience 
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evaluations. Patients weight significantly increased compared to baseline over the course 
of the 6-months in methadone maintenance treatment (MMT). The incidence of sexual 
dysfunction and sleep disorders also significantly increased with MMT.  This study 
examined a larger sample size than many previous studies. The results are comparable 
with other studies suggesting an increase in weight for both male and female patients 
receiving methadone maintenance. The study also highlights other important side effects 
of methadone to consider while providing patient counseling.  
In summary, patients receiving methadone for opioid addiction demonstrate 
significant weight gain. However, the exact mechanisms of this remain unclear. Lack of 
comparison studies using buprenorphine make it difficult to determine if weight gain is 
related to recovery, medication, or other mechanisms. Mysels et al. (2011) found similar 
weight gain for naltrexone and methadone. Although Kolarzyk et al. (2005) found a 
decrease in BMI in female patients, it should be noted that the sample size was very small 
(n=7).  More recently published studies with larger sample sizes have shown increase in 
BMI for both female and male patients, one showing a significantly higher increase in 
BMI in females than in males (Fenn et al., 2014). Weight gain among methadone patients 
was clinically significant. 
Sugar cravings in opioid use  
Cirello et al. (1987) conducted an early case control study examining plasma 
glucose and insulin responses to oral and intravenous glucose administration in users of 
heroin and methadone compared to healthy controls.  Both heroin and methadone users 
had altered response to the oral and IV glucose load compared to the case controls with 
lower fasting plasma glucose and significantly higher basal insulin than controls. The 
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acute insulin response in the methadone and heroin users was significantly less than the 
controls. Both groups of opioid users also had increased fasting insulin levels. This 
provided early evidence that heroin and methadone addiction may alter glucose 
metabolism in a pattern similar to what is observed in individuals with non-insulin 
dependent diabetes. Altered glucose metabolism may contribute to weight gain seen in 
opioid addiction. Limitations included that the study was relatively small and lack of 
matched comparison group. 
 Nolan and Scagnelli (2007) conducted a pilot study to examine food preferences 
and eating habits in patients receiving methadone treatment. Food preference and eating 
habit questionnaires were distributed to participants receiving outpatient methadone 
maintenance treatment (n=28) and controls (n=14). Patients on methadone reported 
higher consumption of sweets, higher eagerness to consume sweet foods, and a wish to 
consume larger quantities than healthy controls. In addition to reporting higher 
consumption of sweet foods, methadone patients had higher BMIs overall than controls, 
suggesting a link between methadone, an increased cravings and consumption of sweet 
calorically dense foods, and weight gain. There were several limitations of this study 
including its small sample size with unmatched controls, the food craving instruments 
used were not validated, and height and weight were self reported. Despite these 
limitations, this study provides important preliminary information about potential 
mechanisms of weight gain in methadone treatment including preferences for sweets and 
increased consumption of such foods.  
Mysels and Sullivan (2010) conducted a literature review to explore the 
relationship between opioid use and development of preference for sweet tastes and 
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associated dental pathology, weight gain, and loss of glycemic control. The review 
included studies with patients using heroin and patients receiving methadone treatment. 
No studies were included that examined patients who exclusively abused prescription 
opioids. They found activation of the mu-opioid receptor by methadone or heroin was 
associated with increased palatable (sweet) taste preference, weight gain, and tooth 
decay. Opioid use was also associated with increased hyperglycemia induced by direct 
action on pancreatic islet cells, which has been shown to increase dietary preference for 
sugary foods and associated increased insulin resistance (Reed & Ghodse, 1973; 
Willenbring et al., 1989). Opioid antagonists were not associated with weight gain or 
glycemic dysregulation. Methadone maintained patients were found to be especially 
susceptible to weight gain, poor dentition, and diabetes.  Studies that examined 
buprenorphine effects on weight were not included due to a lack of research in this area. 
This study provides important evidence to the association of sweet taste preference, 
weigh gain, and methadone maintenance. This further supports that hedonic mechanisms 
may be implicated in weight gain in methadone maintenance treatment for opioid 
addiction.  
Food addiction and hedonic eating  
 Through the advancement of imaging technologies, much more is understood 
about the brain activity in addiction. Recent literature suggests that certain foods and food 
additives may trigger addictive processes in the brain similar to those seen in individuals 
with drug addiction. Drugs and food both trigger reinforcing pathways mediated by 
dopamine in the meso-limbic system (Gearhardt, Corbin, & Brownell, 2008).   
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Volkow et al. (2002) examined the role of dopamine in “nonhedonic” food 
motivation. Participants (n=10) were shown pictures of food after being food deprived for 
16-20 hours. The response was monitored through positron emission tomography (PET) 
and raclopride, a dopamine receptor radioligand that binds to the dopamine receptor and 
competes with endogenous dopamine. Subjects were pretreated with methylphenidate in 
order to block the dopamine transporter and amplify any dopamine changes. Food cues, 
in combination with methylphenidate, were associated with an increase in extracellular 
dopamine in the dorsal striatum. The dorsal striatum mediates decision-making, 
especially action selection and initiation (Balleine, Delgado, & Hikosaka, 2007). Food 
cues and increase in extracellular dopamine were associated with increased self-reports of 
hunger and desire for food.  This suggests that dopamine in the dorsal striatum is 
involved in food motivation. No change was seen in the ventral striatum, including the 
nucleus accumbens (NA).  This suggests that dopamine in the dorsal striatum is involved 
in food motivation distinct from dopamine’s role in food motivation related to the NA 
and reward system. Food was not consumed in this study suggesting that without food 
consumption, the reward system associated with those stimuli were not activated.  
A 2011 study examined the neural correlates of addictive-like eating using 
functional magnetic resonance imaging (fMRI) in healthy adults. Forty-eight healthy 
women were recruited with BMIs ranging from normal to obese. Participants with eating 
disorders were excluded. Food addiction scores were compared to fMRI brain activation 
in response to receipt and anticipation of palatable food. Females meeting the threshold 
for food addiction showed similar brain activation on fMRI as was seen in individuals 
with drug addiction – including activation of reward circuitry (dorsolateral prefrontal 
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cortex and caudate, anterior cingulate cortex, medial orbitofrontal cortex, and amygdala) 
and reduced activation of inhibitory regions (lateral orbitofrontal cortex) in response to 
anticipation of food. There was no significant correlation found between food addiction 
scores and BMI. Although the sample size was small, this was the first study to look at 
the relation between food addiction and neural reward activation. Activation of the neural 
rewards system suggests a similar process in the brain in response to food as is found in 
drug addiction (Gearhardt, et al., 2011). It is plausible that individuals who have greater 
susceptibility to drug addiction might also be more susceptible to food addiction due to 
the similar neural pathways and processes.  
 Stojek, Fisher, and MacKillop (2015) utilized drug addiction paradigms to 
understand eating behaviors and motivations for high sugar, high fat food consumption. 
This study utilized an experimental design and well documented addiction paradigm. 
Subjective cravings, relative reinforcing value of foods (RRVfoods), negative and positive 
affect, amount of food consumed, and latency to first bite were measured following 
exposure to food cues. Adults (n=133) who endorsed liking high fat, high sugar snacks 
and denied eating pathology were recruited. Participants were randomly assigned to one 
of two mood conditions – stress or neutral and to one of two cue exposure conditions – 
food cues or neutral cues (office supplies). Participants in the stress condition reported no 
change in craving or in RRVfoods,. Food cues increased participants cravings and 
RRVfoods. No interaction was found between stress and food cues. Calories consumed 
were not different in subjects in either the stress or food cues conditions, but those in the 
food cues condition had shorter latency to first bite. The addiction literature suggests 
guided imagery does not elicit cravings in social drinkers only in those with alcohol use 
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disorder.  Only adults without eating pathology were included, therefore the results may 
not be generalizable to a population with eating pathology.  No biomarkers such as 
cortisol were collected.  This study underlines the role that food cues play in food 
motivation, suggesting that increased food cues created a higher risk for overeating.  
 Gearhardt, Corbin, & Brownell (2009) examined the food addiction literature in 
the context of each diagnostic criterion for dependence in the Diagnostic and Statistical 
Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric 
Association, 2000). The diagnostic criteria for substance dependence in the DSM-IV 
consisted of: tolerance; withdrawal; taking the substance in larger amounts or over a 
longer period than was intended; persistent desire or unsuccessful effort to cut down or 
control substance use; spending a great deal of time in activities necessary to obtain or 
use the substance or to recover from its effects; giving up social, occupational, or 
recreational activities because of substance use; and continuing the substance use with the 
knowledge that it is causing or exacerbating a persistent or recurrent physical or 
psychological problem. The review found increasing evidence to support that a subset of 
people lose control over eating, are unable to abstain from certain types of foods in spite 
of negative consequences, and fail at attempts to reduce intake. The other categories of 
dependence (i.e. tolerance, withdrawal, spending a great deal of time in activities 
necessary to obtain or use the substance or to recover from its effects, and giving up 
social, occupational, or recreational activities because of substance use) have less clear 
evidence from which to draw conclusions.  Collectively, it appears the evidence suggests 
that addictive-like eating may affect a subset of individuals.   
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Jasinska et al. (2012) explored the role of impulsivity and inefficient inhibitory 
control in individuals with unhealthy eating behaviors. Structural equation modeling was 
utilized to explore in-depth relationships among impulsivity, inhibitory control, eating 
behavior, and body mass index.  Undergraduates (n=210) with BMIs ranging from 
underweight to obese were recruited.  Impulsivity and inhibitory control deficits were 
associated with overeating in response to food cues, negative emotional states, and 
making food choices based on health preferences - not health value.  Participants with 
lower inhibition were more likely to eat more unhealthy foods and had lower intake of 
healthy foods. Unhealthy eating behaviors and choices were associated with an increased 
BMI. This suggests there similar biological mechanisms involve in food and drug 
addiction. Impulsivity and inhibitory control deficits may put individuals at higher risk 
for both drug and food addiction.  
How prevalent is substitute addiction? 
Substitute addiction, also known as addiction transfer or cross-addiction, is a 
phenomenon that occurs when a person replaces one compulsive behavior that causes 
impairment with another (McFadden, 2010). Sussman and Black (2008) describe 
substitute addition as “any addictive behavior that serves at least one key function 
previously achieved by another addictive behavior (e.g., relaxation, escape, excitement, 
pleasure, reduction of negative affect, social lubrication).”  Although there have been 
anecdotal discussions of substitute addiction in the recovery community, there is little 
empirical research on the topic. In a 2007 literature review, 27 webpages on a Google 
Scholar search and 2 articles in a search of OvidMEDLINE and PsycINFO were found on 
the topic (Sussman & Black, 2008).  As early as 1966, the concept of substitute addiction 
	  	   16	  
was being discussed in the literature. One of the earliest studies on the topic by Valiant 
(1966) included food, in addition to marijuana, chloriazepoxide, religion, and 
participation in alcoholics anonymous, as common substitute addictions in narcotic 
abusers. A 2012 literature review found an increase in the prevalence of eating disorders 
in particular bulimia nervosa in patients with concomitant drug use disorder compared to 
the general population (Nøkleby, 2012). 
In a retrospective chart review, Kleiner et al. (2004) examined the relationship 
between obesity and alcohol consumption. An inverse relationship was found between 
BMI and alcohol consumption in women (n=298) who were in active weight 
management. Obese patients had lower rates of alcohol use than the general population. 
The authors hypothesize that overeating may compete with alcohol in the reward system 
in the brain, suggesting that one substance may be able to replace another in the reward 
circuit of the brain.  
Although the empirical evidence on substitute addiction is limited, there is 
significant anecdotal support of this phenomenon in the recovery literature. Utilizing this 
framework, it is plausible that food addiction may serve as a substitute addiction for those 
in recovery for opioid addiction and food may fill one or more key functions (relaxation, 
pleasure, escape, etc) that opioid addiction had previously served for patients. These key 
functions might be related to the reward pathway in the meso-limbic dopamine reward 
circuit. It is also plausible that those who are more susceptible to drug addiction may be 
more susceptible to food addiction both in terms of brain chemistry as well as impulsivity 
and inhibitory control.  The research suggests a relationship between methadone use and 
weight gain; opioid intake appears to correlate with increased sugar intake; and food 
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addiction follows similar pathways in the brain to opioid addiction. The proposed 
research will provide further understanding of the relationships among these phenomena 
and, in particular, of the hedonic mechanisms of weight gain in medication assisted 
treatment for opioid addiction. In addition, it may contribute to future research aimed at 
gathering empirical evidence on substitute addiction.  
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Hedonic Mechanisms of Weight Changes in Medication Assisted Treatment for 
Opioid Addiction  
Abstract 
Background and purpose: Opioid abuse and addiction affects more than 2.4 million 
people in the United States. Medication assisted therapy (MAT) with methadone or 
buprenorphine, along with behavioral counseling, is considered the most effective 
treatment for opioid use disorders. Previous research has found clinically significant 
weight gain with methadone treatment for opioid addiction, but the mechanisms behind 
weight gain remain unclear. The purpose of this study was to determine if hedonic eating 
behaviors, sugar cravings, and addictive like eating was related to weight gain in opioid 
addicted patients receiving buprenorphine/naloxone (Suboxone™) and methadone. 
Methods: Patients undergoing MAT (n=113) completed three questionnaires to measure 
hedonic eating and sugar craving.  A chart review was completed to determine baseline 
weight and weight changes over time.  Results: No differences were found between the 
medication groups in terms of mean age, weight at entry, BMI at entry, race, sex, and 
smoking and Hepatitis C status. A subset of 38 participants was analyzed for weight 
changes over time. Weight gain in patients receiving methadone was evident with no 
weight changes for those receiving Suboxone™. There were no differences in food 
addiction scores, hedonic eating behaviors, and food cravings between the medication 
groups. Both medication groups demonstrated higher levels of cravings and “giving in” 
to those cravings for sweets than for fats. Conclusions: Our findings demonstrate that 
individuals receiving methadone for MAT have greater weight gain than individuals 
receiving Suboxone™. The groups had similar eating behaviors suggesting that weight 
gain associated with methadone may not be attributable to hedonic eating.   
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1. Introduction 
Opioid abuse and addiction affect over 2.4 million people in the United States. In 
2014, 1.9 million people abused prescription pain medication and 586,000 people were 
addicted to heroin (Substance Abuse and Mental Health Services Administration, 2015). 
Medication assisted therapy (MAT), in combination with counseling, is recognized as the 
most effective treatment for patients with opioid use disorders (Stotts, Dodrill, & Kosten, 
2009).  Both buprenorphine and methadone maintenance have been shown to reduce rates 
of illicit drug use, deaths from overdose, risky behavior linked to HIV and Hepatitis C 
transmission, crime, and overall mortality (Thomas et al., 2014). Although research 
supports the use of MAT for opioid addiction, it is not without adverse effects. Several 
studies document clinically significant weight gain (i.e. >5% of baseline) as a side effect 
associated with methadone maintenance posing additional risks unrelated to substance 
addition (Mysels et al., 2011; Fenn et al., 2014). Obesity is associated with higher risk for 
many serious diseases and health conditions including hypertension, type II diabetes, 
stroke, anxiety, depression, several types of cancers, heart disease, and overall mortality 
(Centers for Disease Control, 2014).  Further, a 5% increase in weight from baseline 
increases risk of hypertension, hyperlipidemia, diabetes, and heart disease (Donnelly et 
al, 2009).  
The exact mechanisms associated with weight gain for individuals receiving 
methadone maintenance remain unclear.  Weight changes associated with 
buprenorphine/naloxone (Suboxone™) have not been documented. Methadone’s strong 
affinity for the mu-opioid receptor makes it highly effective in MAT. However, 
preclinical trials from animal studies suggest that agonism of the mu-opioid receptor in 
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certain areas of the brain, specifically in the nucleus accumbens, hypothalamus, and 
paraventricular nucleus, may increase the craving for and consumption of sugar rich 
foods and certain carbohydrates (Mysels et al., 2010). Further, clinical studies have 
shown methadone maintained patients report increased consumption of highly-sweetened 
foods (Kolarzy et al., 2005). Similar findings regarding sugar craving, sugar 
consumption, and weight gain associated with Suboxone™ are not well documented. 
There is a growing body of research demonstrating that particular foods and food 
additives, including sweets, act on similar neural pathways as addictive drugs (Gearhardt 
et al., 2011; Volkow et al., 2002). Gearhardt et al. (2011) examined neural pathways of 
addictive like eating in women using functional magnetic resonance imaging (fMRI).  
Participants meeting the threshold for food addiction showed similar brain activation on 
fMRI that is seen in individuals with drug addiction – including activation of reward 
circuitry (dorsolateral prefrontal cortex and caudate, anterior cingulate cortex, medial 
orbitofrontal cortex, and amygdala) and reduced activation of inhibitory regions (lateral 
orbitofrontal cortex) in response to anticipation of food. It is plausible that some of the 
weight gain seen in methadone maintenance might be attributable to hedonic preferences 
toward highly sweetened foods. Agonism of the mu-receptor in these key neural reward 
pathways may potentiate the hedonic response for sweet foods and beverages.  
Differences between the binding properties of buprenorphine and methadone might 
explain the anecdotal reports of sugar cravings in methadone but not in 
buprenorphine/naloxone.  
The purpose of this study was to determine if hedonic eating behaviors, sugar 
cravings, and addictive like eating were related to weight gain in opioid addicted patients 
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receiving medication assisted therapy. A secondary aim was to determine differences 
between weight gain and eating behaviors for individuals receiving methadone compared 
to individuals receiving Suboxone™ for MAT. Our hypothesis was that hedonic eating 
behaviors and increased food addiction symptom scores would be associated with weight 
gain in medication assisted treatment for opioid addiction for both methadone and 
Suboxone™. Despite the hedonic mechanisms, we expected greater cravings for sweets 
and carbohydrates and higher associated weight gain in individuals receiving methadone 
compared to those receiving Suboxone™. 
2. Methods 
Patients enrolled in medication assisted treatment for opioid addiction in an 
outpatient treatment facility in the northeastern United States were recruited for this 
study.  Inclusion criteria consisted of: English speaking individuals 18 years of age and 
older receiving either methadone or buprenorphine/naloxone (Suboxone™) daily, 
receiving treatment for at least six months, and who were at a stable medication dose. 
Exclusion criteria included women who were pregnant and breastfeeding women while 
receiving MAT.  
Following informed consent, participants completed three validated eating 
behavior surveys. A chart review was conducted. Demographic data (i.e age, gender, 
ethnicity), height and weight upon entry into treatment, most recent weight, weight time 
interval, MAT medication (methadone or Suboxone™), medication dose, other 
concurrent medications, smoking status, and duration in program were collected. This 
study was approved by the University’s Institutional Review Board prior to the onset of 
the study.  
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2.1 Measures 
The Food Craving Inventory (FCI) (White et al., 2002) is a validated 28-item self-
administered instrument used to determine specific food cravings. It was developed using 
two subscales: subjective cravings and consumption of particular foods. Subjective 
cravings were found to correlate with consumption. Frequency of cravings is rated on a 
5-point Likert scale ranging from 1 (“not at all”) to 5 (“nearly every day”). The inventory 
contains four scales that measure high fats, sweets, carbohydrates/starches, and fast-food 
fats.  
The Yale Food Addiction Scale (YFAS) (version 2.0, Gearhardt, Corbin, & Brownell, 
2009) is a validated 25-item self-report questionnaire. It is used to identify symptoms of 
addictive-like eating and food addiction. Food addiction is present when three or more 
symptoms of addictive like eating are endorsed and at least one of two of clinical 
significance items (i.e impairment or distress) are endorsed (Gearhardt, Corbin, & 
Brownell, 2009).  
The Power of Food Scale (PFS) (Lowe et al., 2009) is a validated 15-question self-
administered questionnaire used to evaluate the impact food-abundant environments by 
evaluating appetite for palatable foods. It assesses the psychological impact independent 
of homeostatic hunger. Higher scores suggest greater appetitive responsiveness (Laurent 
& Sibold, 2016; Lowe et al., 2009). 
2.2 Analysis 
T-tests were computed to compare means of continuous variables between medication 
groups for age, weight at entry, body mass index (BMI) at entry, addictive like eating, 
appetitive responsiveness, and food craving. Chi-sqaure tests were used to compare 
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differences in race, sex, smoking status, Hepatitis C status, and the presence or absence of 
food addiction between the two medication groups. T-test was used to compare mean 
BMI change and mean weight change between medication groups. Analysis of 
covariance was computed to determine if BMI and weight change were associated with 
length of time in treatment, food craving, appetitive responsiveness, and food addiction 
scores, and if those associations were different between medication groups. Significance 
was set at α=.05, two sided. Data was analyzed using SPSS v. 23 (IBM Corp, 2015). 
3. Results 
One hundred twenty surveys were completed. One hundred thirteen 
(methadone=63, Suboxone™= 50) met inclusion criteria and were analyzed. Those that 
were omitted were excluded based on the following: two participants received only 
buprenorphine (Subutex™), two were excluded for duplicate data, and three were 
excluded for treatment duration less than six months. Baseline and follow up BMI data 
was available for 38 participants (methadone=29, Suboxone™=9) and was analyzed for 
weight and BMI changes over time. One participant from the Suboxone™ group was 
excluded from sub-group analysis for a reported weight loss of 50 pounds in two months.  
 Patient characteristics are presented in Table 1. Medication groups were not 
statistically different for mean age, weight at entry, and BMI at entry.  There were no 
between group differences for sex, race, smoking status, and Hepatitis C status. Patients 
receiving methadone had significant increase in BMI and weight. Sub-group analysis 
using Levene’s test assuming unequal variances (p < 0.01) demonstrated a mean BMI 
increase of 1.37 kg/m2, (p<0.05) translating to a mean increase of 10.48 pounds (p<0.01) 
in the methadone group over the course of an average of 16 months.  Patients receiving 
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Suboxone™ did not have significant change in BMI (p>0.9) over time.    
No significant differences were found between the MAT groups for YFAS 
symptoms count, food addiction, food craving/give in sub scores and aggregate scores, 
and appetitive responsiveness.  Participants in both medication groups had significantly 
higher cravings and gave into these cravings (p<0.01) more frequently for sugars than for 
fats. 
4. Discussion 
Our findings indicate that individuals receiving methadone for MAT have 
significant weight gain during treatment. Conversely, receiving Suboxone™ maintenance 
was weight neutral. The average weight gain in the methadone group was 6%, which is 
clinically significant and associated with an increased risk of hypertension, 
hyperlipidemia, diabetes, and heart disease (Donnelly et al, 2009). The range of weight 
change was from -20 to 48 pounds. Our findings are consistent with previous studies 
showing gain in methadone maintenance. For example, Mysels et al. (2011) reported a 
10-pound weight gain in the first six months of methadone MAT.  Fenn et al. (2014) 
found a 17.8-pound weight gain within approximately the first two years of treatment. 
Okruhlica and Slexakova (2012) found that weight gain attributed to MAT  plateaued at 
approximately 2 years following the initiation of methadone MAT. Although our data 
showed similar weight gain overall, the weight changes observed in our sample we did 
not find a significant relationship between time in treatment and methadone MAT 
reported in previous studies. This may be attributed to our small sample size between 
groups and the variability of time between such measurements (1.25-71 months).  
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Previous research suggested that patients enter opioid treatment underweight and 
malnourished (Gronbladh & Ohlund, 2011; Okruhlica & Slezakova, 2008) and have 
attributed in-treatment weight gain associated with methadone treatment to an overall 
improvement in nutritional status.  The mean BMI at entry into treatment was 27.0 kg/m2 
for the methadone group and 25.2 kg/m2 for the Suboxone™ group, meaning that 
individuals were overweight upon initiating MAT. This is consistent with more recent 
research by Fenn et al. (2014) who found patients initiating treatment, on average, are 
overweight rather than underweight. Thus, clinical consideration should be given when 
prescribing methadone to an already overweight population. Given the more current 
research and the ongoing obesity epidemic using methadone MAT may be creating 
additional obesity related health risks to a population that is already high risk of co-
morbidities associated with substance dependence and addiction.  
We were unable to isolate predictors of weight gain. Thirty eight percent of 
individuals receiving methadone had clinically significant weight gain. Those with 
clinically significant weight change gained, on average, greater than 28 pounds.  This 
suggests that a subset of individuals may be more susceptible to weight gain and the 
weight gain for these individuals may be greater than suggested by mean weight change 
of the entire sample. Further research is indicated to determine predictors of weight gain 
during treatment. Proposed mechanisms include genetics, physical activity, and 
individualized response to drug pharmacodynamics.    
Interestingly, we did not find any relationship between hedonic eating, appetitive 
responsiveness, and addictive like eating in either the methadone or Suboxone™ groups.  
Our original hypothesis that hedonic eating was a contributing factor to weight gain more 
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specifically in the methadone MAT was not supported. Previous research and anecdotal 
reports from individuals receiving methadone MAT suggests that such individuals have 
an increased preference for sweet foods. Mysels et al. (2010) reported that individuals 
using both methadone and heroin showed increased preference for sweet tastes and 
associated dental pathology compared to healthy controls. Both groups had mean scores 
demonstrating higher sweet cravings (i.e. sometimes to often) when compared to fat 
cravings (i.e. rarely to sometimes). Participants mean scores for giving in to sweet 
cravings were high (i.e. sometimes to often) for both groups compared to scores for 
giving in to fat cravings (i.e. rarely to sometimes). This suggests that methadone and 
Suboxone™ may both be associated with an increase in sweet preferences over other 
types of palatable foods high in fat. Increased craving and giving in to such cravings of 
highly sweetened foods does not appear to contribute to weight gain as previously 
proposed. We, however, did not evaluate the dietary intake of our participants.  Further 
studies should examine craving as well as total dietary intake.  
4.1 Limitations 
Limitations exist. The study was limited by a small sample size. In particular, 
only a small subset of participants had recorded weight information over time thus 
limiting generalization of our findings. Our sample was primarily White in a rural setting 
enrolled in MAT.  Further, we did not evaluate other potential contributing factors such 
as psychotropic medications and co-morbid conditions other than Hepatitis C that may 
affect weight gain and weight status.  Physical activity levels were not examined.  It is 
plausible that physical activity levels differ among treatment groups related to potential 
drug side effects such as drowsiness and fatigue that are generally associated with 
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methadone (Truven Health Analytics, 2011).  
Additionally, we did not assess diet pre-treatment, and a complete food inventory, 
including sugar-sweetened beverages, was not obtained. It is plausible that the food-
craving inventory utilized in this study is appropriate for a population who is comparing 
craving related to opioids to that of various types of food, including sugar. The Food 
Craving Inventory uses the term “cravings” to illicit an individual’s desire to consume 
certain foods. The concept of craving for food, including sugar, may not be an 
appropriate measure for individuals with a history of opioid cravings. Future research 
should include psychometric testing in substance abusing populations.  Similarly, the 
Food Addiction Scale uses scoring similar to what is used to score other forms of 
substance abuse. This scale may be interpreted differently by individuals with a history of 
substance abuse compared to a population without a history of substance addiction.  
5. Conclusions 
Our findings demonstrate that individuals receiving methadone for MAT have 
clinically significant weight gain whereas individuals receiving Suboxone™ do not 
exhibit similar weight changes. Weight gain does not appear to be related to addictive 
like eating, food craving, and appetitive responsiveness. Both groups had high mean 
scores for sweet cravings when compared to other types of foods. As our sample was 
overweight upon entry into MAT, individuals recovering from drug addiction who are 
treated with methadone maintenance may be at greater risk for obesity and its associated 
co-morbidities – thus adding one more significant health problem.  As a result, potential 
weight gain associated with methadone treatment should be an important clinical 
consideration prior to initiating MAT.  Further, patients should be informed of the 
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benefits and risks of treatment, including weight gain for individuals receiving 
methadone MAT. Increased attention should be directed to providing appropriate patient 
education and weight-related counseling throughout MAT.  
Only approximately one third of our participants had recorded weight data over 
time. In order to better understand weight change in methadone and 
buprenorphine/naloxone MAT, more attention should be focused on weight monitoring in 
outpatient treatment. Further, longitudinal research that examines hedonic eating 
behaviors during MAT would provide more insight into the mechanisms of weight 
change.  
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Table 1. Characteristics of Sample (N=113)* 
 
 Medication Count  
Mean Age Methadone 
Suboxone™ 
63 
50 
35.67 
34.94 
Mean Weight at Entry Methadone 
Suboxone™ 
59 
42 
173.66 
161.07 
BMI at Entry Methadone 
Suboxone™ 
59 
42 
27.02 
26.62 
% Male Methadone 
Suboxone™ 
28 
15 
44.4% 
30% 
% Smoker Methadone 
Suboxone™ 
47 
41 
78.3% 
85.4% 
% Hepatitis C Positive Methadone 
Suboxone 
16 
18 
26.2% 
37.5% 
 
* not significant at p<0.05, 2 sided  
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